Biotech Industry · global
Johnson & Johnson to acquire Ollin for $2.2 billion upfront, betting on a dual-target retinal antibody
OLN324 aims to block both VEGF and Ang2 to improve retinal disease control; Blackstone has separately committed $750 million to support Phase 3 development. With funding and pharmaceutical development resources in place, whether it can ease patients’ treatment burden remains a question for clinical results.
For patients who may gradually lose their sight, expectations for treatment extend beyond disease control to how long its effects can last. Johnson & Johnson announced on November 16 that it had agreed to acquire Ollin Biosciences for $2.2 billion upfront, centered on OLN324, an ophthalmic bispecific antibody entering Phase 3 development. The deal brings a major pharmaceutical company’s development resources to the drug candidate, but more durable disease control remains a goal awaiting validation.
OLN324 targets two signaling pathways associated with retinal disease: vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). It is being developed for uses including wet age-related macular degeneration and diabetic macular edema. Johnson & Johnson said the antibody uses a smaller protein format called a “minibody” and has greater potency against Ang2, with the aim of improving control of retinal fluid and further extending treatment intervals.
However, features of the molecular design cannot yet be equated directly with benefits for patients. The transaction announcement did not include complete comparative data sufficient to assess differences in efficacy. Whether OLN324 can deliver better vision outcomes, fewer treatments, and acceptable safety must still be tested in Phase 3 trials. The company’s stated best-in-class potential should be viewed as a development aspiration.
The transaction value also reflects this unfinished path to validation. In addition to the $2.2 billion upfront payment, Ollin shareholders could receive up to approximately $1.125 billion in future regulatory and commercial milestone payments. Johnson & Johnson expects the transaction to close by the end of 2026, subject to applicable regulatory approvals and customary closing conditions. What has been announced is an acquisition agreement; the transaction has not yet closed.
Alongside the acquisition is a separate development funding arrangement. Under an agreement between Johnson & Johnson and Blackstone Life Sciences, contingent on completion of the acquisition, Blackstone will pay a total of $750 million over multiple years to fully fund OLN324’s Phase 3 development. In return, Blackstone will be eligible to receive certain regulatory and sales milestone payments, as well as single-digit percentage royalties on sales. This funding is separate from the acquisition price and also entails sharing future proceeds.
Dow Jones reported confirmation of the acquisition and development financing terms, noting that Ollin had only completed a $330 million Series B financing co-led by ARCH and TCGX in June of this year. Earlier this year, Blackstone also partnered with Johnson & Johnson to support development of the acute myeloid leukemia drug candidate bleximenib. A similar funding arrangement now extends to ophthalmology. For OLN324, the next key question has shifted from securing trial funding to whether clinical evidence can fulfill the treatment expectations behind this investment.